SCHEMBL1999131

SCHEMBL1999131

O=S(=O)(Nc1cc(Cl)cc(Cc2nc3cc(Cl)ccc3s2)c1)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.46
PPARG P37231 4/20 0.43
CYP3A4 P08684 1/20 0.43
AKR1B1 P15121 3/20 0.42
AKR1A1 P14550 1/20 0.42
MCL1 Q07820 1/20 0.40
SGK1 O00141 1/20 0.40
P2RX1 P51575 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CDK2 P24941 1/20 0.38
CDK7 P50613 1/20 0.38
CCNH P51946 1/20 0.38
CCNA1 P78396 1/20 0.38
CDK6 Q00534 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997951 0.91 LOXL2 (0.43) PPARGCYP3A4MAPTLOXL2HSD11B1
SCHEMBL1998122 0.89 TRPV1 (0.48) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL1998293 0.86 TRPV1 (0.48) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL1996983 0.85 TRPV1 (0.48) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL2001870 0.84 TRPV1 (0.50) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL2006100 0.83 LMNA (0.41) TRPV1MAPTCDK1CCNB1CCNA2
SCHEMBL2004113 0.82 TRPV1 (0.48) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL2005058 0.82 PPARG (0.47) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL1996930 0.81 TRPV1 (0.51) TRPV1PPARGCYP3A4AKR1B1AKR1A1
SCHEMBL1999303 0.80 TRPV1 (0.46) TRPV1PPARGCYP3A4AKR1B1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD TRPV1 1349/4885PPARG 2/4885CYP3A4 675/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD TRPV1 1349/4885PPARG 2/4885CYP3A4 675/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD TRPV1 1349/4885PPARG 2/4885CYP3A4 675/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD TRPV1 1412/4885PPARG 1/4885CYP3A4 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.